Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DKK2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DKK2 ECD-Fc / His-Tagged Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View DKK2 Products |
| Gene Delivery | DKK2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional assays. |
View DKK2 Products |
| Benchmark Ab | Anti-DKK2 Recombinant Antibody High-affinity positive control for ELISA, Flow Cytometry, and neutralization assays. |
View DKK2 Products |
| Validator | DKK2 siRNA Set Target-specific knockdown verification in target-expressing cancer cell lines. |
View DKK2 Products |
| Related Target A | DKK1 Critical for family-wide selectivity profiling and counter-screening to prevent off-target toxicity. |
View DKK1 Products |
| Related Target B | LRP6 Primary functional co-receptor of DKK2; essential for downstream Wnt/beta-catenin signaling modulation assays. |
View LRP6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dickkopf Family Cross-Reactivity (DKK1/3/4) | Sequence-verified human/cyno/mouse ortholog proteins available with >95% purity for precise selectivity screening. |
| Disulfide-Rich Conformational Integrity | HEK293 eukaryotic host expression ensures native post-translational modifications and correct disulfide folding of cysteine-rich domains (CRD1 & CRD2). |
| Lack of Validated Positive Controls | Sequence-defined, recombinant biosimilar antibodies included for assay calibration. |
| In Vitro Validation Noise | Sequence-verified siRNA pool included for target-specific gene knockdown validation. |
Live DKK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Dickkopf-2 (DKK2) is emerging as a major frontier in cancer immunotherapy. While historically studied as a modulator of the Wnt/beta-catenin signaling cascade, contemporary oncology research highlights DKK2 as an immune evasion factor that suppresses NK cell and CD8+ T cell activation. The therapeutic pipeline is transitioning from broad Wnt pathway inhibition to highly targeted, immune-restoring anti-DKK2 monoclonal and bispecific antibodies.
As next-generation immunotherapies advance, the focus is shifting toward combining DKK2 blockade with traditional immune checkpoint inhibitors (such as anti-PD-1/PD-L1) to overcome resistance in cold tumors, particularly in colorectal, gastric, and prostate cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Invenra, Leap Therapeutics (DKK Program) | Colorectal Cancer, Melanoma, Solid Tumors | High-affinity screening & species cross-reactivity profiling (HEK293-expressed DKK2-Fc). |
| Bispecific / Multi-specific | Academic Spin-offs, Biotech Startups | PD-1 Resistant Colorectal Cancer | Simultaneous binding assays (Requires highly stable LRP6 and DKK2 recombinant targets). |
| Lentiviral Overexpression | Translational Research Labs | Immunological Co-culture Assays | Stable cell lines (Lentivirus) to evaluate NK cell suppression and cytotoxicity recovery. |